Search

Nigg L, Schanz U, Ambühl PM, Fehr J, Bachli EB. Prolonged course of pure red cell aplasia after erythropoietin therapy. Eur J Haematol 2004: 73: 376–379.© Blackwell Munksgaard 2004.Pure red cell aplasia (PRCA) caused by neutralising anti-erythropoietin antibodies is a very rare disease. Since 1998, an increased incidence of PRCA in patients with kidney failure following treatment with recombinant human erythropoietin (rhEpo) has been reported, mostly in Europe. In most cases, PRCA was cured by immunosuppressive therapy, immunoglobulins, plasmapheresis or renal transplantation. We report an exceptionally prolonged course of PRCA over 68 months despite renal transplantation and different immunosuppressive regimens. [ABSTRACT FROM AUTHOR]

Thomas PG, Ishihara K, Vaidya S, Gugliuzza KK. Campath and renal transplant rejection.Clin Transplant 2004 DOI: 10.1111/j.1399-0012.2004.00288.x© Blackwell Munksgaard, 2004No clear guidelines exist for the treatment of acute vascular rejection following renal transplantation. This report documents one patient who was treated with plasmapheresis, immunoglobulin and Campath with good initial response. However, rejection recurred resulting in graft loss and, in addition, the patient developed post-transplant lymphoma. [ABSTRACT FROM AUTHOR]

Reviews the book "Plasma Separation and Plasma Fractionation: Current Status and Future Directions," edited by M.J. Lysaght.

Reviews the book "Plasmapheresis and Plasma Exchange," vol. 1, by T.J. Hamblin.